NCT04177706View on ClinicalTrials.gov

Ketamine for the Treatment of Opioid Use Disorder and Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

November 21, 2022

Study Completion Date

November 21, 2022

Conditions
DepressionOpioid-use DisorderOpioid Abuse
Interventions
DRUG

Ketamine Hydrochloride

Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.

DRUG

Placebo

Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Medical University of South Carolina

OTHER

NCT04177706 - Ketamine for the Treatment of Opioid Use Disorder and Depression | Biotech Hunter | Biotech Hunter